Indagoo

Targetmol

Immunoglobulin G1 (IgG1), specifically the anti-human interleukin 2 receptor (IL-2R) monoclonal antibody CHI621, is a recombinant therapeutic protein designed for targeted immunotherapy. This dimeric structure consists of two heavy chains (γ1-chain) and two light chains, linked by disulfide bonds, which confer stability and functionality. IgG1 is characterized by its ability to bind specifically to the IL-2 receptor, a critical component in immune response regulation, making it valuable in treating conditions such as autoimmune diseases and certain cancers. The antibody's structure allows for high specificity and affinity towards its target, facilitating effective immune modulation. Additionally, the human-mouse chimeric nature of CHI621 reduces the likelihood of immunogenicity compared to fully murine antibodies, enhancing its therapeutic potential in human applications. The CAS number 179045-86-4 uniquely identifies this compound, aiding in its classification and regulatory processes. Overall, CHI621 exemplifies the advancements in monoclonal antibody technology, providing targeted treatment options in clinical settings.

Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 γ1-chain), disulfide with human-mouse monoclonal CHI621 light chain, dimer

179045-86-4: Immunoglobulin G1 (IgG1), specifically the anti-human interleukin 2 receptor (IL-2R) monoclonal antibody CHI621, is a recombinant therapeutic protein designed for targeted immunotherapy. This dimeric structure consists of two heavy chains (γ1-chain) and two light chains, linked by disulfide bonds, which confer stability and functionality. IgG1 is characterized by its ability to bind specifically to the IL-2 receptor, a critical component in immune response regulation, making it valuable in treating conditions such as autoimmune diseases and certain cancers. The antibody's structure allows for high specificity and affinity towards its target, facilitating effective immune modulation. Additionally, the human-mouse chimeric nature of CHI621 reduces the likelihood of immunogenicity compared to fully murine antibodies, enhancing its therapeutic potential in human applications. The CAS number 179045-86-4 uniquely identifies this compound, aiding in its classification and regulatory processes. Overall, CHI621 exemplifies the advancements in monoclonal antibody technology, providing targeted treatment options in clinical settings.

Basiliximab: chimeric IgG1 antibody inhibiting interleukin-2 receptor, used for kidney transplant immunosuppression.

CAS 179045-86-4

Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 γ1-chain), disulfide with human-mouse monoclonal CHI621 light chain, dimer

Basiliximab

Ref: TM-T73698

Unii-9927mt646m

Ref: IN-DA00AMBD